Strong Tower Advisory Services Takes Position in TransMedics Group, Inc. $TMDX

Strong Tower Advisory Services acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the first quarter, Holdings Channel reports. The fund acquired 8,891 shares of the company’s stock, valued at approximately $884,000.

Other institutional investors have also made changes to their positions in the company. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the 3rd quarter valued at $29,000. Allworth Financial LP raised its stake in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Optiver Holding B.V. raised its stake in TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the period. Finally, LOM Asset Management Ltd bought a new position in shares of TransMedics Group during the third quarter valued at $34,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $78.79 on Monday. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The firm has a market cap of $2.72 billion, a PE ratio of 17.91 and a beta of 1.92. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The business has a fifty day moving average of $83.39 and a 200-day moving average of $112.53.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. On average, equities research analysts predict that TransMedics Group, Inc. will post 1.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the topic of several recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Stifel Nicolaus lifted their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $134.50.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.